What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly

References

• SahaS, ChantD, WelhamJ, McGrathJ. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141. doi:10.1371/journal.pmed.002014115916472
   PubMed Web of Science ®Google Scholar
• AndreasS, SchulzH, VolkertJ, et al. Prevalence of mental disorders in elderly people: the European MentDis_ICF65+ study. Br J Psychiatry. 2017;210(2):125–131. doi:10.1192/bjp.bp.115.18046327609811
   PubMed Web of Science ®Google Scholar
• SandersJL. A distinct language and a historic Pendulum: the evolution of the diagnostic and statistical manual of mental disorders. Arch Psychiatr Nurs. 2011;25(6):394–403. doi:10.1016/j.apnu.2010.10.00222114794
   PubMed Web of Science ®Google Scholar
• LiA, JiSM, YueWH, et al. Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. BMJ Open. 2018;8(8):e020070. doi:10.1136/bmjopen-2017-020070
   PubMed Web of Science ®Google Scholar
• VancampfortD, StubbsB, MitchellAJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–347. doi:10.1002/wps.2025226407790
   PubMed Web of Science ®Google Scholar
• HiemkeC, BergemannN, ClementHW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–2):e1. doi:10.1055/s-0037-160099129390205
   PubMed Web of Science ®Google Scholar
• CallaghanJT, BergstromRF, PtakLR, BeasleyCM. Olanzapine. pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177–193. doi:10.2165/00003088-199937030-0000110511917
   PubMed Web of Science ®Google Scholar
• TsudaY, SaruwatariJ, Yasui-FurukoriN. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014;4(3):e004216. doi:10.1136/bmjopen-2013-004216
   PubMed Web of Science ®Google Scholar
• CastbergI, WestinAA, SkogvollE, et al. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 2017;136(5):455–464. doi:10.1111/acps.1279428865402
   PubMed Web of Science ®Google Scholar
• DengSH, WangZZ, LuHY, et al. A retrospective analysis of steady-state olanzapine concentrations in chinese patients using therapeutic drug monitoring: effects of valproate and other factors. Ther Drug Monit. 2020;42(4):636–642. doi:10.1097/FTD.000000000000073832039940
   PubMed Web of Science ®Google Scholar
• StentzelU, BergNVD, SchulzeLN, et al. Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla). BMC Psychiatry. 2018;18(1):155. doi:10.1186/s12888-018-1737-429843676
   PubMed Web of Science ®Google Scholar
• BigosKL, BiesRR, PollockBG. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry. 2006;14(12):993–1003. doi:10.1097/01.JGP.0000224330.73063.6c17138806
   PubMed Web of Science ®Google Scholar
• SajatovicM, LevinJ, Fuentes-CasianoE, CassidyKA, TatsuokaC, JenkinsJH. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication. Compr Psychiatry. 2011;52(3):280–287. doi:10.1016/j.comppsych.2010.07.00221497222
   PubMed Web of Science ®Google Scholar
• OsterbergLG, UrquhartJ, BlaschkeTF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88(4):457–459. doi:10.1038/clpt.2010.17120856243
   PubMed Web of Science ®Google Scholar
• HaddadPM, BrainC, ScottJ. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62. doi:10.2147/PROM.S4273525061342
   PubMedGoogle Scholar
• LawMR, SoumeraiSB, Ross-DegnanD, AdamsAS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47–53. doi:10.4088/JCP.v69n010718312037
   PubMed Web of Science ®Google Scholar
• DaviesEA, O’MahonyMS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015;80(4):796–807. doi:10.1111/bcp.1259625619317
   PubMed Web of Science ®Google Scholar
• KrauseM, HuhnM, Schneider-ThomaJ, RotheP, SmithRC, LeuchtS. Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(12):1360–1370. doi:10.1016/j.euroneuro.2018.09.00730243680
   PubMed Web of Science ®Google Scholar
• IwataY, NakajimaS, CaravaggioF, et al. Threshold of dopamine d2/3 receptor occupancy for hyperprolactinemia in older patients with schizophrenia. J Clin Psychiatry. 2016;77(12):e1557–e1563. doi:10.4088/JCP.15m1053828086010
   PubMed Web of Science ®Google Scholar
• MaharajAR, WuH, ZimmermanKO, et al. Population pharmacokinetics of olanzapine in children. Br J Clin Pharmacol. 2021;87(2):542–554. doi:10.1111/bcp.1441432497307
   PubMed Web of Science ®Google Scholar
• NiXJ, WangZZ, ShangDW, LuHY, ZhangM, WenYG. Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1092:506–514. doi:10.1016/j.jchromb.2018.05.026
   Web of Science ®Google Scholar
• YinAY, ShangDW, WenYG, LiL, ZhouTY, LuW. Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis. Eur J Clin Pharmacol. 2016;72(8):933–944. doi:10.1007/s00228-016-2040-227117554
   PubMed Web of Science ®Google Scholar
• BigosKL, PollockBG, ColeyKC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48(2):157–165. doi:10.1177/009127000731038518199892
   PubMed Web of Science ®Google Scholar
• JovanovićM, VučićevićK, MiljkovićB. Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models. Drug Metab Rev. 2020;52(1):1–18. doi:10.1080/03602532.2020.171751732008418
   PubMed Web of Science ®Google Scholar
• WangCY, JiaoZ, DingJJ, YuEQ, ZhuGX. Remedial dosing recommendations for delayed or missed doses of valproic acid in patients with epilepsy based on Monte Carlo simulations. Epilepsy Behav. 2020;111:107265. doi:10.1016/j.yebeh.2020.10726532640410
   PubMed Web of Science ®Google Scholar
• DingJJ, ZhangYJ, JiaoZ, WangY. The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation. Acta Pharmacol Sin. 2012;33(11):1431–1440. doi:10.1038/aps.2012.13523103621
   PubMed Web of Science ®Google Scholar
• BonatePL. A brief Introduction to monte carlo simulation. Clin Pharmacokinet. 2001;40(1):15–22. doi:10.2165/00003088-200140010-0000211236807
   PubMed Web of Science ®Google Scholar
• NguyenTH, CometsE, MentréF. Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model. J Pharmacokinet Pharmacodyn. 2012;39(5):499–518. doi:10.1007/s10928-012-9264-222886041
   PubMed Web of Science ®Google Scholar
• WangZZ, ZhangYF, HuangWC, et al. Effects of comedication and genetic factors on the population pharmacokinetics of Lamotrigine: a prospective analysis in Chinese patients with epilepsy. Front Pharmacol. 2019;10:832. doi:10.3389/fphar.2019.0083231404235
   PubMed Web of Science ®Google Scholar